Skip to main content

Idaho · Schedule I · The state is closing doors, not opening them

Idaho is the one state actively making reform harder.

Idaho stands out for moving in the opposite direction from the national trend. Psilocybin and psilocin are Schedule I under Idaho Code § 37-2705, with felony penalties for possession, cultivation, and distribution, and the state even restricts mushroom spores. No decriminalization or research bill has advanced. More striking is what is advancing: a certified 2026 ballot measure that would reserve to the Idaho Legislature alone the authority to legalize marijuana, narcotics, or other psychoactive substances — removing citizens' ability to do so by initiative. Where most states are debating how to open access, Idaho is debating how to bolt the doors shut.

90-second quick read · research companion

Need the full research version?

This is the 90-second cliff-note read on imicrodosing.net. For the cited deep-dive companion, read the full .org research page before moving into product decisions.

Read the full .org research companion → Browse related 90-second reads →
Sch. IFelony penalties
§ 37-2705Idaho Code
2026Lock-down measure
NoneReform bills

Doors being closed

Reform routes bolted shut

Most states have at least one open route to reform — a bill, a ballot path, a city ordinance. Idaho is narrowing them. The routes below show which are shut, which are being shut, and which barely remain.

Which reform routes are open

Legislative reform

Shut

No psilocybin decriminalization or research bill has advanced. Felony penalties remain under § 37-2705.

Citizen ballot initiative

Being shut

A certified 2026 measure would reserve drug-legalization power to the legislature, removing the initiative route.

Mushroom spores

Shut

Idaho is among the states that prohibit psilocybin-capable spores, closing even a gray-area path.

Local decriminalization

Closed

No Idaho city has decriminalized, and there is no established municipal path to do so.

Why this shape

A state tightening, not loosening

Idaho is a useful counter-case. While the national conversation is about access frameworks and research funds, Idaho's active move is restrictive: a ballot measure to take the legalization question away from voters entirely and hand it to the legislature, which has shown no appetite for reform. Combined with felony penalties and a spore ban, the picture is of a state deliberately closing routes. Psilocybin is Schedule I, and the trend line points toward more restriction, not less.

Three cities

Where Idaho's stance holds

Idaho's strict status applies uniformly across its population centers. Boise is the capital and largest city, where the legislature sits. Idaho Falls anchors the east. Nampa anchors the Treasure Valley west of Boise.

Common questions

Idaho psilocybin FAQ

Q · 01

Is psilocybin legal in Idaho?

No. Psilocybin and psilocin are Schedule I under Idaho Code § 37-2705, with felony penalties for possession, cultivation, and distribution. Idaho has some of the strictest psychedelic laws in the country.

Q · 02

What is the 2026 Idaho ballot measure about?

A certified 2026 measure would provide that only the Idaho Legislature has authority to legalize marijuana, narcotics, or other psychoactive substances, and would remove the ability for citizens to initiate statutes legalizing these substances. It is a restriction on the reform path, not a reform.

Q · 03

Are mushroom spores legal in Idaho?

Idaho is among the states that prohibit the sale or possession of spores capable of producing psilocybin mushrooms, closing a path that remains gray-area in some other states.

Q · 04

Has any Idaho city decriminalized psilocybin?

No. No Idaho municipality has decriminalized psilocybin, and there is no established local path to do so. The state's felony Schedule I prohibition applies uniformly.

While psilocybin stays Schedule I

iMicrodosing.com ships lab-verified products within all applicable federal, state, and local laws. For deeper research and clinical context on psilocybin therapy outcomes, imicrodosing.org aggregates the trial literature.